ZMB Member Martin Schuler
ZMB Member
Martin Schuler
Next ZMB-Member
Prof. Dr. Martin Schuler
Director of:
Department of Medical Oncology
University Hospital Essen
Hufelandstraße 55
45147 Essen
- +49 201 723 2000
- Website
- Selected Publications
-
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
Clinical research
- Gastrointestinal oncology
- Interdisciplinary oro-oncology
- Palliative medicine
Translational and clinical-related basic research
- Sarcomas
- Pancreatic tumors
- Digestive tract tumors
- Lung tumors
Selected Publications
-
Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”In: Annals of Oncology Vol. 32 (2021) Nr. 1, pp. 126
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : Clinical and biomarker results from a phase I trialIn: Annals of Oncology (2020)
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
The quest for efficient trial designs in precision oncologyIn: The Lancet Oncology Vol. 21 (2020) Nr. 12, pp. 1539 - 1541
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus : the MONO studyIn: Annals of Oncology Vol. 30 (2019) Nr. 9, pp. 1487 - 1495
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer : A Phase 1b Clinical TrialIn: JAMA Oncology Vol. 5 (2019) Nr. 2, pp. e184475
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ -
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancerIn: Annals of Oncology Vol. 30 (2019) Nr. 4, pp. 655 - 657
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2/3 trialIn: The Lancet Vol. 393 (2019) Nr. 10184, pp. 1948 - 1957
ISSN: 0140-6736; 0023-7507; 1474-547XOnline Full Text: dx.doi.org/ -
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion studyIn: The Lancet Oncology Vol. 20 (2019) Nr. 10, pp. 1454 - 1466
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 studyIn: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
ISSN: 0923-7534; 1569-8041 -
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)In: Annals of Oncology Vol. 28 5 (2017) -
ISSN: 0923-7534; 1569-8041 -
First-line afatinib for advanced EGFRm1 NSCLC : Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trialsIn: Ann Oncol Vol. 28 2 (2017) -
ISSN: 0923-7534; 1569-8041 -
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trialIn: Annals of Oncology Vol. 28 (2017) Nr. 5, pp. 1084 - 1089
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Inactivation of Capicua drives cancer metastasisIn: Nature Genetics Vol. 49 (2017) Nr. 1, pp. 87 - 96
ISSN: 1061-4036; 1546-1718Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Vol. 8 (2017) pp. 14447
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7In: Ann Oncol Vol. 28 5 (2017) -
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)In: Annals of Oncology Vol. 27 (2016) Nr. Supplement 6, pp. vi427
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) : updated results from the multicentre, open-label, phase 1 trialIn: The Lancet Oncology Vol. 17 (2016) Nr. 4, pp. 452 - 463
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trialIn: Annals of Oncology Vol. 27 (2016) Nr. 3, pp. 417 - 423
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trialIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl.6, pp. 508P
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) : phase 2 resultsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii127 - ii128
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma : post hoc analyses of the randomized LUX-Lung 3 and 6 trialsIn: Annals of Oncology Vol. 27 (2016) Nr. 11, pp. 2103 - 2110
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIOIn: The Lancet Oncology Vol. 17 (2016) Nr. 12, pp. 1697 - 1708
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
IMAB362 : a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancerIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii141 - ii142
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by AddeoIn: Annals of Oncology Vol. 27 (2016) Nr. 6, pp. 1172 - 1173
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levelsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, 360O_PR
ISSN: 1569-8041; 1569-8041Online Full Text: dx.doi.org/ -
Afatinib (a) plus paclitaxel (p) following progression on a monotherapy in patients (pts) with metastatic non-small-cell lung cancer (nsclc) who previously benefited from erlotinib (e)/gefitinib (g) : a global randomised phase iii triallux-lung 5 (ll5)In: Annals of Oncology Vol. 26 (2015) Nr. S 1, pp. i33 - i34
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trialsIn: The Lancet Oncology Vol. 16 (2015) Nr. 2, pp. 141 - 151
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6In: The Lancet Oncology Vol. 16 (2015) Nr. 7, pp. 830 - 838
ISSN: 1474-5488Online Full Text: dx.doi.org/ -
Comprehensive genomic profiles of small cell lung cancerIn: Nature Vol. 524 (2015) Nr. 7563, pp. 47 - 53
ISSN: 1476-4687; 0028-0836Online Full Text: dx.doi.org/ (Open Access) -
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)In: Annals of Oncology Vol. 26 (2015) Nr. S 6, pp. vi73 - vi89
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut) : Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF CohortIn: Annals of Oncology Vol. 26 (2015) Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, pp. i61
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsIn: The New England Journal of Medicine Vol. 373 (2015) Nr. 8, pp. 726 - 736
ISSN: 0028-4793Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Ceritinib in ALK-Rearranged Non–Small-Cell Lung CancerIn: The New England Journal of Medicine Vol. 370 (2014) Nr. 13, pp. 1189 - 1197
ISSN: 0028-4793; 1533-4406Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in Lux-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed EGFR mutation-positive lung cancerIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 410 - 411
ISSN: 0923-7534; 1569-8041 -
Impact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (PTS) with advanced non-small lung cancer (NSCLC) progressing after chemotherapy (CTX) and erlotinib (E) or gefitinib (G) - a single center experienceIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 437 - 438
ISSN: 0923-7534; 1569-8041 -
LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutationsIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 402
ISSN: 0923-7534; 1569-8041 -
Lux-LungG 3 : Afatinib versus cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harboring an EGFR mutationIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 11, pp. 8
ISSN: 0923-7534; 1569-8041 -
Phase IB dose-escalation study of BEZ235 or BKM 120 in combination with paclitaxel (PTX) in patients with advanced solid tumorsIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 157 - 158
ISSN: 0923-7534; 1569-8041 -
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancerIn: Annals of Oncology Vol. 23 (2012) Nr. 9, pp. 2306 - 2313
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerIn: Annals of Oncology Vol. 21 (2010) Nr. 2, pp. 275 - 282
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/